IDXX · Earnings call · 2026Q2T · Full report

Diagnostic Utilization Expansion

IDEXX LABORATORIES INC /DE · 2026-08-04 · Importance 42 · Surprise 40 · In source text

IDEXX VetLab consumable revenue increased 14% organically, driven by net new premium-instrument customers and expanded testing utilization. The company said most U.S. wellness visits still do not include bloodwork, while only around one in ten U.S. wellness visits currently receive bloodwork and the rate is approximately one-third or lower in most countries outside the U.S. New applications including Cancer Dx, inVue Dx FNA, Catalyst SDMA, and expanded Fecal Dx menus are intended to create additional testing episodes and raise diagnostic inclusion without relying on a recovery in visit volume.

Key facts

• Since introducing IDEXX SDMA in 2015, customers have run nearly 120 million patient tests globally.
• Company stated they see early indications that inVue Dx FNA is associated with an increased number of masses evaluated and that rollout broad availability is planned by year end.
• Fecal Dx platform expansions enable detection of 2x more infections than fecal flotations.
• Practices on ezyVet with Vello show higher wellness bloodwork inclusion rates than practices on competitive on-premise PIMS.
• Today, fewer than 10% of lumps and bumps ever get evaluated.
• Approximately 70% of Cancer Dx tests are run as part of a broader bloodwork panel.

Impact estimates